topotecan + dexamethasone + vincristine

This is a combination chemotherapy regimen consisting of three agents: - **Topotecan** is a topoisomerase I inhibitor that interferes with DNA replication and transcription, leading to cell death. It is primarily used as an antineoplastic agent in various cancers. - **Dexamethasone** is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressant properties, commonly used to reduce inflammation and as part of cancer regimens for its lympholytic effects. - **Vincristine** is a vinca alkaloid that inhibits microtubule formation in mitotic spindles, arresting cell division at metaphase. This combination has been studied particularly in pediatric patients with relapsed acute lymphoblastic leukemia (ALL), where it was shown to be effective in inducing remission when administered sequentially or together during induction therapy[1][2][3]. The regimen leverages the complementary mechanisms of action of each drug to maximize cytotoxicity against leukemic cells. Topotecan targets DNA integrity, vincristine disrupts mitosis, and dexamethasone induces apoptosis in lymphoid cells.